Douglas Miehm
Stock Analyst at RBC Capital
(2.24)
# 2,677
Out of 4,944 analysts
46
Total ratings
46.34%
Success rate
-2.56%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Outperform | $8 → $7 | $3.66 | +91.26% | 2 | Aug 7, 2025 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $8 → $9 | $11.32 | -20.49% | 10 | Aug 1, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $7.00 | +42.86% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $13.77 | +23.46% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.86 | +481.19% | 1 | Mar 10, 2025 |
MannKind
Aug 7, 2025
Maintains: Outperform
Price Target: $8 → $7
Current: $3.66
Upside: +91.26%
Aurinia Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $11.32
Upside: -20.49%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $7.00
Upside: +42.86%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $13.77
Upside: +23.46%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.86
Upside: +481.19%